DILIsym Services Inc. Initiates Development of IPFsym™
January 14 2019 - 08:30AM
Business Wire
New idiopathic pulmonary fibrosis QSP
platform to enable more efficient drug development
DILIsym Services Inc., a Simulations Plus company (Nasdaq:SLP)
and a leading provider of simulation and modeling software for
pharmaceutical safety and efficacy, today announced that it is
initiating development of IPFsym™, QSP (quantitative systems
pharmacology) modeling software that will provide the ability to
predict the efficacy of drugs being developed to treat idiopathic
pulmonary fibrosis (IPF). The development of IPFsym is being
sponsored by a large pharmaceutical company partner for $2.7
million, and it will be widely available via licensing and
consulting for the broader pharmaceutical industry upon
completion.
Dr. Scott Q Siler, chief scientific officer of DILIsym Services,
said: “IPF is a fatal lung disease that is characterized by a
progressive loss of lung function. Genetic and environmental
factors compromise the epithelial cells of the lung, leading to
pulmonary fibrosis over time. DILIsym Services is leveraging our
experience in modeling liver fibrosis in non-alcoholic fatty liver
disease with NAFLDsym® to simulate lung fibrosis and other aspects
of IPF. There is substantial effort within the pharmaceutical
industry to develop effective treatments for IPF, and we believe
predictions with QSP modeling software like IPFsym will make the
clinical development process more efficient.”
IPFsym will include key pathophysiologic mechanisms and clinical
aspects of IPF, such as lung fibrosis, alveolar epithelial injury,
pulmonary fibrosis, and test of lung function (e.g., forced vital
capacity--FVC). IPFsym will also include the ability to simulate
disease progression and inter-patient variability in
pathophysiologic and clinical characteristics with SimPops®.
Shawn O’Connor, chief executive officer of Simulations Plus,
DILIsym’s parent company, added: “The sponsored development of
IPFsym will provide a valuable predictive modeling and simulation
tool that can be used to improve the cost and efficiency of drug
development and, importantly, positively support decision making
that can directly impact patient safety. This endeavor is another
example of our leadership in QSP modeling, including the ability to
predict both the efficacy and safety of drugs. Moreover, we are
excited that this effort will also include expansion of our
flagship PBPK modeling software, GastroPlus, to improve the
predictions of compound exposure upon inhalation of drugs.”
IPFsym will be available for licensing and consulting services,
as is the case with DILIsym Services’ other QSP offerings like
DILIsym and NAFLDsym.
About DILIsym Services Inc.
DILIsym Services Inc. was founded in 2015 in Research Triangle
Park, North Carolina, and is the leading provider of drug-induced
liver injury simulation software and related consulting services to
the pharmaceutical industry. The company spun out of the former
Hamner Institutes, acquiring all of the intellectual property,
software, documentation, and other materials for the DILIsym
software. The company’s other products include MITOsym®, for
simulating in vitro mitochondrial function; NAFLDsym®, for the
study of nonalcoholic fatty liver disease – a worldwide disease
with few available treatment options; and a future tool, RENAsym®,
for predicting drug-induced kidney injury. More information is
available on the company’s website at https://www.dilisym.com.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical and biotechnology agents.
Our software is licensed to and used in the conduct of drug
research by major pharmaceutical and biotechnology companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect,” and “anticipate”
mean that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190114005178/en/
Simulations Plus Investor
RelationsMs. Renee
Bouche661-723-7723renee@simulations-plus.com
Hayden IRMr. Cameron
Donahue651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2023 to Mar 2024